hotspot -WSS

hotspot

author：Wikipedia 2025-08-11 09:49:11 - browse：55245

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Editas, Vertex strike deal on CRISPR

Wikipedia

WSS

Putin woos African leaders at a summit in Russia with promises of expanding trade and other ties

Doctors increasingly discourage vaping amid mounting health concerns

Doctors increasingly discourage vaping amid mounting health concerns

Hospitals owned by private equity see complications spike 25%

CRISPR gene editing developments we’re watching in 2024

HCA says smaller share of spending going to labor

hotspot

hotspot

explore

How to save PrEP access — and even expand it

Carvykti CAR

Hollywood unions extend contract negotiations for actors

In Spain, a hospital brews its own CAR

Hollywood unions extend contract negotiations for actors

Virtual care provider acquires bankrupt Pear's prescription apps

Continuity nursing helped my family in our darkest PICU moments

Grail spinoff by Illumina should end disastrous merger attempt

Walensky prepares to leave CDC — and Congress — behind

Virtual care provider acquires bankrupt Pear's prescription apps

knowledge

HCA sued by state AG for quality issues at Mission Health

Medicare Advantage beneficiaries sue Humana over algorithm use

How to keep neuroscience’s past racism from being its future

What STAT readers think about the FDA and patient advocacy

Violet CEO on training clinicians to promote more inclusive care

David Ricks of Eli Lilly: best biopharma CEO of 2023

knowledge

hotspot

Wikipedia

hotspot